The Full Wiki

More info on Rufinamide

Rufinamide: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Rufinamide
Systematic (IUPAC) name
1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Identifiers
CAS number 106308-44-5
ATC code N03AF03
PubChem 129228
Chemical data
Formula C 10H8F2N4O 
Mol. mass 238.194
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

EU EMEA:linkUS FDA:link

Pregnancy cat.  ?
Legal status Prescription only
Routes Oral

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome[1] and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 for the adjunctive treatment for the seizures associated with Lennox–Gastaut syndrome and as adjunctive treatment for partial-onset seizures. It is marketed under the brand name Banzel.[2] It is also marketed in the European Union under the brand name Inovelon.[3]

The mechanism of action of rufinamide is unknown. However, it is presumed to involve stabilization of the sodium channel inactive state, effectively keeping these ion channels closed. Although the direct mechanism of action may be different, several other antiepileptic agents also stabilize a sodium channel inactive state including phenytoin, carbamazepine, and lacosamide (stabilizes the slow inactive state).

References

External links








Got something to say? Make a comment.
Your name
Your email address
Message